首页|颗粒蛋白前体、GATA结合蛋白-6脑胶质瘤组织的表达及其临床意义

颗粒蛋白前体、GATA结合蛋白-6脑胶质瘤组织的表达及其临床意义

扫码查看
目的 探究脑胶质瘤组织中颗粒蛋白前体(PGRN)、GATA结合蛋白-6(GATA6)表达与临床病理特征及预后的关系。方法 选取2017年1月至2019年3月河南大学淮河医院收治的84例脑胶质瘤患者为研究对象,收集脑胶质瘤组织和瘤旁组织标本,随后进行5年随访。采用免疫组织化学法检测组织中PGRN、GATA6蛋白表达;脑胶质瘤组织PGRN、GATA6表达与临床病理特征的关系以例(%)表示,行x2检验;多因素Cox回归分析脑胶质瘤患者预后的影响因素;通过Kaplan-Meier法分析脑胶质瘤患者组织中PGRN、GATA6表达与患者预后的关系。结果 脑胶质瘤组织PGRN阳性表达率高于瘤旁组织(73。81%比40。48%,x2=19。056,P<0。05),GATA6阳性表达率高于瘤旁组织(69。05%比36。90%,x2=17。419,P<0。05);世界卫生组织(WHO)分级为Ⅲ~Ⅳ、分化程度为低分化程度患者PGRN(83。33%、90。63%)、GATA6阳性表达率(79。63%、84。38%)高于WHO分级为Ⅰ~Ⅱ(56。67%、50。00%)、分化程度为高分化程度(63。46%、59。62%)患者(x2=7。094、7。922、7。561、5。682,P<0。05);脑胶质瘤组织PGRN阳性表达患者5年生存率低于PGRN阴性表达患者(32。26%比77。27%,x2=13。351,P<0。05);GATA6阳性表达患者5年生存率低于GATA6 阴性表达患者(31。03%比 73。08%,x2=12。875,P<0。05);PGRN[风险比(HR)=2。398,95%可信区间(CI):1。369~4。200]、GATA6(HR=2。843,95%CI:1。426~5。668)为脑胶质瘤患者死亡的独立危险因素(HR=2。398、2。843,P<0。05)。结论 脑胶质瘤组织中PGRN、GATA6阳性表达率较高,与脑胶质瘤患者病理特征及预后相关,是脑胶质瘤患者死亡的独立危险因素。
Expression and clinical significance of progranulin and GATA binding factor-6 in glioma tissues
Objective To investigate the relationship between the expression of progranulin(PGRN)and GATA binding factor-6(GATA6)in glioma tissue and clinicopathological features and prog-nosis.Methods A total of 84 patients with glioma admitted to Huaihe Hosiptal of Henan University from January 2017 to March 2019 were used as subjects.Glioma tissue and adjacent tissue specimens were col-lected and followed up for 5 years.Immunohistochemical methods were applied to detect the expression of PGRN and GATA6 proteins in tissues.The relationship between the expression of PGRN and GATA6 in glioma tissue and clinical pathological characteristics is expressed as n(%),and a chi square test is per-formed.Multivariate Cox regression was applied to analyze the prognostic factors of glioma patients.Kap-lan-Meier method was applied to analyze the relationship between the expression of PGRN and GATA6 in the tissues of glioma patients and their prognosis.Results The positive expression rate of PGRN in glioma tissues was higher than that in adjacent tissues(73.81%vs.40.48%,x2=19.056,P<0.05),and the positive expression rate of GATA6 in glioma tissues was higher than that in adjacent tissues(69.05%vs.36.90%,x2=17.419,P<0.05).The positive expression rates of PGRN(83.33%,90.63%)and GATA6(79.63%,84.38%)in patients with WHO grades Ⅲ-Ⅳ and low differentiation were higher than those in patients with WHO grades Ⅰ-Ⅱ(56.67%,50.00%)and high differentiation(63.46%,59.62%,x2=7.094,7.922,7.561,5.682,P<0.05).The 5-year survival rate of patients with PGRN positive expression in glioma tissue was lower than that of patients with PGRN negative expression(32.26%vs.77.27%,x2=13.351,P<0.05).The 5-year survival rate of GATA6 positive expression patients was lower than that of GATA6 negative expression patients(31.03%vs.73.08%,x2=12.875,P<0.05).PGRN[hazard ratio(HR)=2.398,95%confidence interval(CI):1.369-4.200]and GATA6(HR=2.843,95%CI:1.426-5.668)were independent risk factors for mortality in glioma patients(HR=2.398,2.843,P<0.05).Conclusion The positive expression rates of PGRN and GATA6 in glioma tissues are relatively high,which are related to the pathological features and prognosis of glioma patients,and they are independent risk factors for mortality in glioma patients.

GliomaProgranulinGATA binding factor-6PrognosisClinical pathological features

苑兵舰、徐晨阳

展开 >

河南大学淮河医院神经外科,开封 475000

脑胶质瘤 颗粒蛋白前体 GATA结合蛋白-6 预后 临床病理特征

2024

中华实验外科杂志
中华医学会

中华实验外科杂志

CSTPCD
影响因子:0.759
ISSN:1001-9030
年,卷(期):2024.41(9)